The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101
Clinical & Manufacturing

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101

JAN 24, 2023
New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits
Clinical & Manufacturing

New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits

JAN 24, 2023
World’s First Computational Reconstruction of a Virus in its Biological Entirety
Infectious Disease & AMR

World’s First Computational Reconstruction of a Virus in its Biological Entirety

JAN 23, 2023
IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Biotics and Supplements

IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections

JAN 16, 2023
Micronoma receives FDA breakthrough device designation for novel liquid biopsy assay for lung carcinoma detection
Oncology

Micronoma receives FDA breakthrough device designation for novel liquid biopsy assay for lung carcinoma detection

JAN 12, 2023
Microbiome Drug Development: 2022 in Review
Editor's Choice

Microbiome Drug Development: 2022 in Review

DEC 30, 2022
Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals
Editor's Choice

Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

DEC 22, 2022
Biomica Raises $20 Million to Advance its Pipeline of Microbiome-based Therapeutics
Finance

Biomica Raises $20 Million to Advance its Pipeline of Microbiome-based Therapeutics

DEC 22, 2022
Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy
Infectious Disease & AMR

Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy

DEC 21, 2022
Beiersdorf acquires S-Biomedic and strengthens expertise in the field of acne treatment
Finance

Beiersdorf acquires S-Biomedic and strengthens expertise in the field of acne treatment

DEC 16, 2022
A Biosolutions Juggernaut: Novozymes and Chr. Hansen to merge into one corporation
Finance

A Biosolutions Juggernaut: Novozymes and Chr. Hansen to merge into one corporation

DEC 13, 2022